Skip to main content

Table 2 Maternal and cord blood folate biomarkers of FASSTT trial participants

From: Effect of continued folic acid supplementation beyond the first trimester of pregnancy on cognitive performance in the child: a follow-up study from a randomized controlled trial (FASSTT Offspring Trial)

 

Placebo (n = 33)

Folic acid (n = 37)

p value

14th GW (pre-intervention)

 Serum folate, nmol/L

48.7 (40.7, 56.7)

45.6 (39.1, 52.1)

0.544

 RBC folate, nmol/L

1109 (846, 1371)

1223 (1025, 1421)

0.312

36th GW (post-intervention)a

 Serum folate, nmol/L

26.0 (18.9, 33.2)

51.1 (43.6, 58.6)

< 0.001

 RBC folate, nmol/L

978 (823, 1133)

1834 (1609, 2060)

< 0.001

 MTHFR 677TT genotype, %

9

16

0.595

Cord bloodb

 Serum folate, nmol/L

71.7 (60.5, 83.0)

99.1 (86.6, 111.6)

0.002

 RBC folate, nmol/L

1535 (1260, 1810)

2177 (1779, 2574)

0.009

 MTHFR 677TT genotype, %

14

9

0.914

  1. Continuous measures presented as mean (95% CI) unless otherwise indicated. Continuous measures compared using independent sample t test. Count measures compared using Pearson’s chi-square
  2. aPost-intervention, following supplementation with folic acid (400 μg/d) for 22 weeks in pregnancy
  3. bCord blood collected upon delivery
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us